ListedMainboardMANKIND
Mankind Pharma Ltd
Mankind Pharma Ltd is a mainboard IPO raising ₹4,326 Cr at ₹1,026 – ₹1,080 a share. It listed on 9 May 2023 and trades at ₹2,620 today, +142.6% against its issue price of ₹1,080. It was subscribed 15× in total.
₹1,080
Issue price
₹2,620
Price now
+142.6%
Since issue price
9 May 2023
Listed on
15×Subscribed (final) · all exchanges
15.3 times more demand than shares on offer
populated partly populated we hold nothing here — the tab says why
Who bid for it
| Investor category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| QIB Banks, funds and other large institutions | 80,11,769 | 39,38,34,103 | 49× |
| Foreign Institutional Investors | no separate quota | 20,94,34,654 | n/a |
| Domestic Financial Institutions | no separate quota | 7,05,36,492 | n/a |
| Mutual funds | no separate quota | 9,80,69,062 | n/a |
| Others | no separate quota | 1,57,93,895 | n/a |
| Non-institutional Wealthy individuals and companies bidding above ₹2 lakh | 60,08,827 | 2,28,22,761 | 3.80× |
| Non Institutional Investors | 40,05,885 | 2,00,00,500 | 4.99× |
| Corporates | no separate quota | 24,07,301 | n/a |
| Individuals | no separate quota | 1,58,40,656 | n/a |
| Others | no separate quota | 17,52,543 | n/a |
| Non Institutional Investors | 20,02,942 | 28,22,261 | 1.41× |
| Corporates | no separate quota | 22,178 | n/a |
| Individuals | no separate quota | 23,37,686 | n/a |
| Others | no separate quota | 4,62,397 | n/a |
| Retail Ordinary investors bidding up to ₹2 lakh | 1,40,20,596 | 1,28,56,038 | 0.92× |
| Cut Off | no separate quota | 1,00,71,061 | n/a |
| Price bids | no separate quota | 27,84,977 | n/a |
| Total | 2,80,41,192 | 42,95,12,902 | 15× |
Sub-categories read no separate quota rather than a dash: the exchange publishes bids at that level but never a reservation against them, so a subscription multiple does not exist — it is not missing data. Bids across both exchanges (NSE and BSE) — the figure usually quoted publicly. Last updated 25 Jul, 07:17 pm IST.
How demand built
We hold no subscription readings for this issue.